Mycophenolate mofetil: a promising immunosuppressive agent.
With avaibility of newer immunosuppressive agents, incidence of acute graft rejection has decreased. Mycophenolate mofetil is one such new drug, now available in the Indian market It has been found to be useful in prevention and treatment of acute and chronic rejection after transplantation. Besides transplant it has been used successfully in primary and secondary glomerulopathies (e.g. SLE) and other autoimmune diseases. The drug is well tolerated with side effects limited mainly to gastrointestinal system in the form of epigastric pain, vomiting and diarrhoea.
Kulkarni
A A
AA
Department of Medicine and Section of Nephrology, Mumbai 400 016, India.
Shah
Bharat V
BV
D000368:Aged; D019540:Area Under Curve; D001682:Biological Availability; D002648:Child; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006084:Graft Rejection / Q000517:prevention & control*; D006207:Half-Life; D006801:Humans; D007166:Immunosuppressive Agents / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D016030:Kidney Transplantation; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use; D014018:Tissue Distribution
D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid